-
Tuesday, June 2nd, 2015
Soligenix Announces Publication of Successful Application of its Heat Stabilization Technology to a Human Papillomavirus Vaccine -
Thursday, May 28th, 2015
Soligenix Announces Collaboration with the University of Hawai’i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine -
Thursday, May 14th, 2015
Soligenix Announces First Quarter 2015 Highlights and Financial Results -
Wednesday, May 13th, 2015
Soligenix Announces Development Agreement with Emergent BioSolutions -
Monday, May 4th, 2015
Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO -
Tuesday, April 14th, 2015
Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn’s Disease -
Tuesday, March 24th, 2015
Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results -
Wednesday, March 11th, 2015
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine -
Thursday, March 5th, 2015
Soligenix to Present at the 27th Annual ROTH Conference -
Tuesday, March 3rd, 2015
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients -
Friday, February 13th, 2015
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC -
Wednesday, February 11th, 2015
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC -
Saturday, February 7th, 2015
FDA Grants Soligenix “Fast Track” Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma -
Thursday, February 5th, 2015
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City -
Monday, February 2nd, 2015
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC -
Thursday, January 29th, 2015
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine -
Monday, January 5th, 2015
Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome -
Monday, December 29th, 2014
Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data -
Wednesday, December 24th, 2014
Soligenix Announces Closing of Public Offering of Units -
Friday, December 19th, 2014
Soligenix Announces Pricing of Public Offering of Units
